Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray

March 31, 2009

GENEVA, Switzerland, March 31 /PRNewswire/ — Viroblock SA has announced
today that the first generation of VCCD Tech antiviral nasal spray
formulation is active against human influenza. Viroblock’s patented
Cholesterol Catalytic Depletion Technology (VCCD Tech) inactivates enveloped
viruses during the extra-cellular phase, by altering and destabilizing
cholesterol-rich viral envelopes.

The two pre-clinical studies exposed ferrets to Influenza A
Wisconsin/67/2005 and influenza A Panama/2007/99 strains, and were conducted
by Retroscreen Virology Ltd, a recognized leader in the research and testing
of antiviral compounds and vaccines. Both the direct inoculation and the
natural transmission protocols have confirmed the effectiveness and the value
of the antiviral nasal spray.

These in-vivo campaigns confirm all in laboratory in-vitro studies to
date and demonstrate that VCCD Tech represents a breakthrough for
inactivating a number of enveloped viruses and their strains.

“Our depletion technology shows no toxicity at the dosage we tested thus
far and allegedly limits the development of any viral resistance, and makes
it effective on all families of enveloped viruses, such as human and avian
influenzas, SARS, AIDS, Ebola and smallpox viruses.”

“This is an exciting development period for Viroblock and the most recent
pre-clinical performance is a testament to our innovative and cutting-edge
technology, the quality of our team, board of directors and investors.”

“We, at Viroblock, leverage all our technological assets for rapidly
developing the next generation of antiviral nasal sprays; I am also confident
that our technology will become an important element of pandemic influenza
preparedness efforts”.

“Our ability to deliver tailored antiviral formulations, which can exist
as colloidal suspensions, gels, creams, and aerosol sprays, opens promising
business opportunities and a bright future for Viroblock.”, comments CEO

Thierry Pelet.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a
pioneer and world leader in the blocking virus transmission technology.

Its patented VCCD technology allegedly inactivates all families and
strains of enveloped viruses, like human and avian influenzas, RSV, SARS,
AIDS, Ebola and smallpox viruses, and leverages a mechanism of action that
limits the development of any viral resistance and toxicity. VCCD Tech
products exist as colloidal suspensions, gels, creams, and aerosol sprays,
having specific mechanical, physical and chemical properties

The W.A. De Vigier Foundation nominated Viroblock SA as one of the 10
best technology projects of the year 2006, and the Swiss Tech Tour 2007
Selection Committee has rated Viroblock SA as part of the top 50 technology
companies in Switzerland.

Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide
expert in artificial and bio-membranes, and non-phospholipid vesicles.

    Additional information is available on the company's website at



    Thierry Pelet
    Chief Executive Officer
    Viroblock SA
    Phone: +41-22-884-83-44
    E-Mail: t.pelet@viroblock.com

SOURCE Viroblock SA

Source: newswire

comments powered by Disqus